Katherine Perkey

TL;DR: The evidence of persistent replication associated with apparently suboptimal drug concentrations argues for development and evaluation of novel therapeutic strategies that will fully suppress viral replication in lymphatic tissues to avert the long-term clinical consequences of chronic immune activation driven directly or indirectly by low-level viral replication to thereby improve immune reconstitution.

TL;DR: The estimated size of the residual tissue burden of 108 vDNA+ cells potentially containing replication-competent proviruses, along with evidence of continuing virus production in LT despite ART, indicated two important sources for rebound following treatment interruption.

TL;DR: Recrudescent infection was detectable in multiple different LTs, and the population was genetically diverse, consistent with reactivation from a larger number of cells, underscore the challenges facing strategies to eradicate HIV infection.

TL;DR: Analysis of LT samples from macaques prior to and during combination antiretroviral therapy demonstrated that B cell follicles are an important anatomical compartment for both latent and active viral persistence during treatment, and developed a specific and sensitive next-generation in situ hybridization approach to detect vRNA.

TL;DR: The in vivo efficacy of a targeted cytotoxic therapy to kill infected cells that persist despite long-term ART is determined and it is found that compared to ART alone, this agent profoundly depleted productively infected cells systemically.